サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1722614

神経モジュレーションの世界市場レポート：技術別、生体材料別、用途別、地域別、2025年～2033年

Neuromodulation Market Report by Technology, Biomaterial, Application, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 150 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.12円
神経モジュレーションの世界市場レポート：技術別、生体材料別、用途別、地域別、2025年～2033年
出版日: 2025年05月01日
発行: IMARC
ページ情報: 英文 150 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の神経モジュレーション市場規模は2024年に82億米ドルに達しました。今後、IMARC Groupは、同市場が2033年までに188億米ドルに達し、2025年～2033年の成長率（CAGR）は9.2％に達すると予測しています。同市場は、慢性疾患や神経疾患の有病率の増加、有利な規制環境の導入、ヘルスケア支出の増加、デバイス技術の著しい進歩、低侵襲（MI）治療への需要の高まり、研究開発（R&D）イニシアティブへの強力な投資に支えられ、力強い成長を遂げています。

神経モジュレーション市場分析：

主な市場促進要因：神経モジュレーション市場は、パーキンソン病、慢性疼痛、うつ病などの慢性疾患や神経疾患の有病率の増加によって牽引されています。さらに、ヘルスケアへの支出の増加、償還政策の改善を提供する有利な規制の実施、磁気共鳴画像装置（MRI）セーフで充電可能なデバイスの開発を含む神経モジュレーションデバイスの急速な技術進歩が、市場の成長を後押ししています。

主な市場動向：神経モジュレーションデバイスに人工知能（AI）や機械学習（ML）技術を統合し、リアルタイムモニタリングや治療の調整を可能にする動きがあります。さらに、現在進行中の調査や臨床試験の成功により、神経モジュレーション治療の適応症が拡大し、市場も拡大しています。

地理的動向：北米が神経モジュレーション市場を独占しているのは、その先進的なヘルスケアインフラ、強固な規制枠組み、高額な医療費によるものです。その他の地域も、ヘルスケアインフラの改善、可処分所得の増加、神経モジュレーション療法に対する認知度の高まりなどを背景に急成長を遂げています。

競合情勢：神経モジュレーション業界の主な市場参入企業には、Abbott Laboratories、Bioventus Inc.、Boston Scientific Corporation、Helius Medical Technologies、Integer Holdings Corporation、LivaNova PLC、Medtronic plc、MicroTransponder Inc.、Neuronetics、NeuroPace Inc.、NeuroSigma Inc.、Nevro Corp.などがあります。

課題と機会：主な課題は、機器や手技のコストが高いことであり、特に新興国市場における市場浸透が制限される可能性があります。加えて、機器移植の複雑さや潜在的な副作用もハードルとなっています。しかし、肥満や依存症といった未開拓の病態に対する潜在的な治療など、神経モジュレーションの応用範囲の拡大にはビジネスチャンスがあります。さらに、ヘルスケア支出の増加は、これまでサービスが行き届いていなかった領域への市場拡大の大きなチャンスとなります。

神経モジュレーション市場動向：

慢性疾患と神経疾患の有病率の上昇

糖尿病、肥満、心血管疾患などの慢性疾患や、パーキンソン病、てんかん、うつ病などの神経疾患の罹患率の増加は、神経モジュレーション市場の重要な促進要因となっています。米国疾病予防管理センター（CDC）によると、米国では成人の10人に6人が慢性疾患を患っています。また、10人中4人が2つ以上の慢性疾患を抱えています。また、インドの老年成人の約21％が少なくとも1つの慢性疾患を抱えています。農村部では17％、都市部では29％の老人が少なくとも1つの慢性疾患に苦しんでいます。これらの健康問題は合併症を引き起こし、神経モジュレーション療法によって管理・治療することができます。例えば、脊髄刺激療法（SCS）は、背部手術失敗症候群や複合性局所疼痛症候群に起因する症状の疼痛緩和のために広く使用されています。

ヘルスケアへの支出の増加

世界のいくつかの国では、ヘルスケアへの支出の増加、中間層の人口増加、高度な医療インフラの整備により、神経モジュレーション療法の導入が増加しています。例えば、インドのヘルスケアに対する公的支出は、23年度にはGDPの2.1％、22年度には2.2％に達しています。また、インド政府は同国のヘルスケア・インフラを強化するため、5万ルピー（68億米ドル）相当の信用優遇制度の導入を計画しています。同様に欧州では、2022年の一般政府医療支出は1兆2,210億ユーロ、GDPの7.7%に達しました。米国のヘルスケア支出は4.1％増加し、4兆5,000億米ドル、1人当たり1万3,493米ドルに達しました。このような拡大は、神経モジュレーション業界の地理的な足跡を増やし、これらの先進治療を新たな患者集団に導入しています。

有利な償還政策の実施

神経モジュレーション治療に対する償還政策の継続的な改善は、市場成長を促進する主な要因です。多くの国々で、難治性疾患の治療における神経モジュレーションの有用性が認識されたため、医療保険プロバイダーはいくつかの神経モジュレーション治療を含めるよう方針を改定しています。このような変化により、神経モジュレーション技術はより幅広い患者にとって利用しやすいものとなっています。2022年、米国では92.1％にあたる3億400万人が、その年のある時点で健康保険に加入していた（米国国勢調査局調べ）。さらに、民間の医療保険加入率は公的保険加入率を上回り、それぞれ65.6％、36.1％でした。また、保険会社は、特に入院日数の短縮や薬物使用量の削減という点で、長期的に神経モジュレーションの費用対効果を認めており、保険償還の適用範囲が拡大しています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の神経モジュレーション市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：技術別

  • 内部神経モジュレーション
    • 主要セグメント
      • 脊髄刺激療法（SCS）
      • 脳深部刺激療法（DBS）
      • 迷走神経刺激（VNS）
      • 仙骨神経刺激（SNS）
      • 胃電気刺激（GES）
  • 外部神経モジュレーション
    • 主要セグメント
      • 経皮的電気神経刺激（TENS）
      • 経頭蓋磁気刺激（TMS）
      • その他

第7章 市場内訳：生体材料別

  • 金属バイオマテリアル
  • 高分子バイオマテリアル
  • セラミックバイオマテリアル

第8章 市場内訳：用途別

  • パーキンソン病
  • てんかん
  • うつ
  • ジストニア
  • 疼痛管理
  • その他

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Bioventus Inc.
    • Boston Scientific Corporation
    • Helius Medical Technologies
    • Integer Holdings Corporation
    • LivaNova PLC
    • Medtronic plc
    • MicroTransponder Inc.
    • Neuronetics
    • NeuroPace Inc.
    • NeuroSigma Inc.
    • Nevro Corp.
図表

List of Figures

  • Figure 1: Global: Neuromodulation Market: Major Drivers and Challenges
  • Figure 2: Global: Neuromodulation Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Neuromodulation Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Neuromodulation Market: Breakup by Technology (in %), 2024
  • Figure 5: Global: Neuromodulation Market: Breakup by Biomaterial (in %), 2024
  • Figure 6: Global: Neuromodulation Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Neuromodulation Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Neuromodulation (Internal Neuromodulation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Neuromodulation (Internal Neuromodulation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Neuromodulation (External Neuromodulation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Neuromodulation (External Neuromodulation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Neuromodulation (Metallic Biomaterials) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Neuromodulation (Metallic Biomaterials) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Neuromodulation (Polymeric Biomaterials) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Neuromodulation (Polymeric Biomaterials) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Neuromodulation (Ceramic Biomaterials) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Neuromodulation (Ceramic Biomaterials) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Neuromodulation (Parkinson's Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Neuromodulation (Parkinson's Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Neuromodulation (Epilepsy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Neuromodulation (Epilepsy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Neuromodulation (Depression) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Neuromodulation (Depression) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Neuromodulation (Dystonia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Neuromodulation (Dystonia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Neuromodulation (Pain Management) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Neuromodulation (Pain Management) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Neuromodulation (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Neuromodulation (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: North America: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: North America: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: United States: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: United States: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Canada: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Canada: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Asia-Pacific: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Asia-Pacific: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: China: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: China: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Japan: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Japan: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: India: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: India: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: South Korea: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: South Korea: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Australia: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Australia: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Indonesia: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Indonesia: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Others: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Others: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Europe: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Europe: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Germany: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Germany: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: France: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: France: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: United Kingdom: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: United Kingdom: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Italy: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Italy: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Spain: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Spain: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Russia: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Russia: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Latin America: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Latin America: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Brazil: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Brazil: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Mexico: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Mexico: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Others: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Others: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Middle East and Africa: Neuromodulation Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Middle East and Africa: Neuromodulation Market: Breakup by Country (in %), 2024
  • Figure 78: Middle East and Africa: Neuromodulation Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Global: Neuromodulation Industry: SWOT Analysis
  • Figure 80: Global: Neuromodulation Industry: Value Chain Analysis
  • Figure 81: Global: Neuromodulation Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Neuromodulation Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Neuromodulation Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 3: Global: Neuromodulation Market Forecast: Breakup by Biomaterial (in Million USD), 2025-2033
  • Table 4: Global: Neuromodulation Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Neuromodulation Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Neuromodulation Market: Competitive Structure
  • Table 7: Global: Neuromodulation Market: Key Players
目次
Product Code: SR112025A5722

The global neuromodulation market size reached USD 8.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 18.8 Billion by 2033, exhibiting a growth rate (CAGR) of 9.2% during 2025-2033. The market is experiencing robust growth, driven by the increasing prevalence of chronic and neurological disorders, imposition of favorable regulatory environment, rising expenditure on healthcare, significant advancements in device technology, and growing demand for minimally invasive (MI) therapies, supported by strong investment in research and development (R&D) initiatives.

Neuromodulation Market Analysis:

Major Market Drivers: The neuromodulation market is driven by the increasing prevalence of chronic diseases and neurological disorders, such as Parkinson's disease, chronic pain, and depression. Moreover, the rising expenditure on healthcare, the implementation of favorable regulations that offer improvements in reimbursement policies, and rapid technological advancements in neuromodulation devices, including the development of magnetic resonance imaging (MRI)-safe and rechargeable devices, are boosting the market growth.

Key Market Trends: There is a trend towards the integration of artificial intelligence (AI) and machine learning (ML) technologies into neuromodulation devices that enable real-time monitoring and adjustments of therapy. Moreover, the expansion of indications for neuromodulation therapies, facilitated by ongoing research and successful clinical trials, is broadening the market expansion.

Geographical Trends: North America dominates the neuromodulation market due to its advanced healthcare infrastructure, robust regulatory framework, and high healthcare expenditure. Other regions are also experiencing rapid growth, driven by improving healthcare infrastructures, increasing disposable incomes, and growing awareness of neuromodulation therapies.

Competitive Landscape: Some of the major market players in the neuromodulation industry include Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., and Nevro Corp., among many others.

Challenges and Opportunities: A major challenge is the high cost of devices and procedures, which can limit market penetration, especially in developing regions. Additionally, the complexity of device implantation and potential side effects pose hurdles. However, opportunities lie in the expanding scope of neuromodulation applications, including potential treatments for untapped medical conditions, such as obesity and addiction. Furthermore, increasing healthcare spending presents a significant opportunity for market expansion into previously underserved areas.

Neuromodulation Market Trends:

Rising Prevalence of Chronic Diseases and Neurological Disorders

The heightened incidence of chronic diseases such as diabetes, obesity, and cardiovascular conditions, alongside neurological disorders like Parkinson's disease, epilepsy, and depression, is a significant driver for the neuromodulation market. As per the Centre for Disease Control and Prevention (CDC), 6 in 10 adults in the U.S. are suffering from chronic diseases. And 4 out of 10 people have more than two chronic conditions. Also, about 21% of the geriatric adults in India have at least one chronic disease. 17% of geriatric people in rural areas and 29% in urban areas suffer from at least one chronic disease. These health issues lead to complications that can be managed or treated through neuromodulation therapies. For instance, spinal cord stimulation (SCS) is widely used for pain relief in conditions that result from failed back surgery syndrome or complex regional pain syndrome.

Increasing Expenditure on Healthcare

Several countries across the globe are witnessing increased adoption of neuromodulation therapies owing to rising expenditure on healthcare, the growing population of the middle class, and the establishment of advanced healthcare infrastructures. For instance, India's public expenditure on healthcare touched 2.1% of GDP in FY23 and 2.2% in FY22. Also, the Indian government is planning to introduce a credit incentive program worth Rs. 50,000 crores (US$ 6.8 billion) to boost the country's healthcare infrastructure. Similarly, in Europe, the general government spending on health amounted to €1221 billion or 7.7% of GDP in 2022. The U.S. healthcare spending saw a hike of 4.1%, reaching $4.5 trillion or $13493/person. This expansion is increasing the geographical footprint of the neuromodulation industry and introducing these advanced therapies to new patient populations.

Implementation of Favorable Reimbursement Policies

The ongoing improvements in reimbursement policies for neuromodulation procedures is a main factor driving the market growth. In many countries, health insurance providers have revised their policies to include several neuromodulation therapies as they recognize their benefits in treating many refractory conditions. These changes have made neuromodulation technologies more accessible to a broader range of patients. In 2022, 92.1 percent of people, or 304.0 million in the U.S., had health insurance at some point during the year, as per the U.S. Census Bureau. Moreover, private health insurance coverage was more prevalent than public coverage, at 65.6 percent and 36.1 percent, respectively. Also, insurers are recognizing the cost-effectiveness of neuromodulation in the long term, especially in terms of reduced hospital stays and medication use, which is expanding the scope of reimbursement coverage.

Neuromodulation Market Segmentation:

Breakup by Technology:

  • Internal Neuromodulation
  • Spinal Cord Stimulation (SCS)
  • Deep Brain Stimulation (DBS)
  • Vagus Nerve Stimulation (VNS)
  • Sacral Nerve Stimulation (SNS)
  • Gastric Electrical Stimulation (GES)
  • External Neuromodulation
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Transcranial Magnetic Stimulation (TMS)
  • Others

Internal neuromodulation accounts for the majority of the market share

Based on the neuromodulation market analysis and forecast, internal neuromodulation emerged as the largest segment. It includes advanced therapies, such as spinal cord stimulation (SCS), deep brain stimulation (DBS), sacral nerve stimulation (SNS), and vagus nerve stimulation (VNS), among others. They are utilized for treating a wide range of chronic conditions and neurological disorders, including chronic pain, Parkinson's disease, urinary and fecal incontinence, and refractory epilepsy. Moreover, the proven efficacy of internal neuromodulations in improving patient outcomes, significant advancements in device technology that enhance user safety and comfort, and the broadening scope of clinical applications are fueling the neuromodulation market revenue.

Breakup by Biomaterial:

  • Metallic Biomaterials
  • Polymeric Biomaterials
  • Ceramic Biomaterials

Metallic biomaterials hold the largest share of the industry

As per the neuromodulation market report and overview, metallic biomaterials stand out as the largest segment, owing to their critical role in the manufacturing of implants and devices used in neuromodulation therapies, such as electrodes and leads. Metallic biomaterials are favored for their superior electrical conductivity, biocompatibility, and durability. They are essential for ensuring the long-term reliability and performance of neuromodulation devices, particularly those that require chronic implantation or are subject to bodily fluids and tissues. Besides this, the ongoing advancements that improve their functionality and safety, such as coatings to enhance biocompatibility or technologies to reduce the risk of infection, are favoring the neuromodulation market growth.

Breakup by Application:

  • Parkinson's Disease
  • Epilepsy
  • Depression
  • Dystonia
  • Pain Management
  • Others

Parkinson's disease represents the leading market segment

According to the neuromodulation market outlook and trends, Parkinson's disease emerged as the largest segment, reflecting the significant impact and utility of neuromodulation therapies in managing chronic neurological disorders. The increasing utilization of deep brain stimulation (DBS) for the treatment of patients who do not respond adequately to pharmacological treatments is enhancing the market growth. DBS helps in alleviating symptoms such as tremors, rigidity, and bradykinesia, significantly enhancing the quality of life for patients. Moreover, the efficacy of neuromodulation in providing substantial and sustained symptom relief, leading to its widespread adoption in clinical settings, is catalyzing the neuromodulation market share.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest neuromodulation market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for neuromodulation.

North America accounted for the largest segment in the neuromodulation market, attributed to several key factors, including advanced healthcare infrastructure, strong regulatory support, and substantial investments in research and development (R&D). Moreover, the region is a hub of some of the leading companies in the neuromodulation industry, which drives innovation and market growth through continuous advancements in technology. Additionally, the high prevalence of chronic diseases and neurological disorders, coupled with a well-established healthcare system that facilitates early adoption of new technologies, is contributing to the neuromodulation market revenue.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the neuromodulation industry include Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., Nevro Corp., etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The top neuromodulation companies are engaged in enhancing their competitive edge through strategic initiatives, such as mergers, acquisitions, and partnerships. They are investing in research and development (R&D) to innovate and improve their neuromodulation devices. These innovations focus on increasing the precision, effectiveness, and safety of therapies for conditions like chronic pain, Parkinson's disease, and urinary disorders. Additionally, industry leaders are involved in clinical trials to expand the indications for existing technologies, thereby broadening the potential user base. They are also prioritizing obtaining regulatory approvals in new markets to ensure global access to their advanced therapies. Furthermore, major companies are enhancing patient and practitioner engagement through digital platforms that facilitate better monitoring and management of therapy outcomes. This helps them align with the broader trend toward digital health solutions in medical technology, thereby positively impacting the neuromodulation market's recent development and opportunities.

Neuromodulation Market News:

In April 2022, Boston Scientific Corporation (US) received FDA approval for its Vercise Neural Navigator with visualization software, STIMVIEW XT. The device allows medical professionals to view the real-time location of leads, or electrodes, in patients with Parkinson's disease and those undergoing deep brain stimulation (DBS).

In December 2022, Abbott Laboratories received FDA approval for its Eterna spinal cord stimulation (SCS) system. It is a small implantable and rechargeable spinal cord stimulator for treating chronic pain. The neuromodulation device utilizes Abbott's proprietary low-dose BurstDR stimulation.

Key Questions Answered in This Report

  • 1.How big is the neuromodulation market?
  • 2.What is the future outlook of neuromodulation market?
  • 3.What are the key factors driving the neuromodulation market?
  • 4.Which region accounts for the largest neuromodulation market share?
  • 5.Which are the leading companies in the global neuromodulation market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Neuromodulation Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Internal Neuromodulation
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Spinal Cord Stimulation (SCS)
      • 6.1.2.2 Deep Brain Stimulation (DBS)
      • 6.1.2.3 Vagus Nerve Stimulation (VNS)
      • 6.1.2.4 Sacral Nerve Stimulation (SNS)
      • 6.1.2.5 Gastric Electrical Stimulation (GES)
    • 6.1.3 Market Forecast
  • 6.2 External Neuromodulation
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Transcutaneous Electrical Nerve Stimulation (TENS)
      • 6.2.2.2 Transcranial Magnetic Stimulation (TMS)
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Biomaterial

  • 7.1 Metallic Biomaterials
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Polymeric Biomaterials
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Ceramic Biomaterials
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Parkinson's Disease
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Epilepsy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Depression
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Dystonia
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Pain Management
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bioventus Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Boston Scientific Corporation
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Helius Medical Technologies
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Integer Holdings Corporation
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 LivaNova PLC
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Medtronic plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 MicroTransponder Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Neuronetics
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 NeuroPace Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
    • 14.3.11 NeuroSigma Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Nevro Corp.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials